The company said it is evaluating its strategic options regarding ADX-097 as it shifts efforts over to pushing bempikibart.

Q32 Bio Inc. (Nasdaq: QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing biologic therapeutics to restore immune homeostasis, today announced a corporate restructuring to ...

Atopy from food allergies to environmental factors can increase hair loss prevalence among children and adults, according to ...

Panelists discuss how switching therapies in patients with alopecia areata (AA) is often necessary when initial treatments ...

A phase 3 study demonstrated that ritlecitinib was effective and well tolerated in patients with alopecia areata and ≥ 25% ...

BMO Capital Markets adjusted its stance on Q32 Bio Inc. (NASDAQ: QTTB), downgrading the biotechnology firm's stock rating from Outperform to Market Perform, accompanied by a significant decrease in ...

The risk for alopecia areata is increased among patients with lower serum levels of vitamin D and zinc, but no relationship was observed with copper.

WALTHAM, Mass. - Q32 Bio Inc. (NASDAQ: QTTB), a clinical-stage biotechnology firm trading at $3.18 with a market cap of $38.55 million, announced a strategic shift to prioritize the development of its ...

Neehar Sachdeva is a popular Instagram influencer who recently got married and is trending as she is suffering from Alopecia.

BMO Capital downgraded Q32 Bio (QTTB) to Market Perform from Outperform with a price target of $3, down from $22. The company announced an ...

The goal is to find a cure for alopecia areata, an autoimmune disease that causes hair loss in distinct round patches.

Q32 Bio (QTTB) announced a corporate restructuring to focus on the advancement of its bempikibart clinical development program for the ...